Mechanism of the neurotoxicity of MPTP. An update

T P Singer1, R R Ramsay

  • 1Department of Biochemistry-Biophysics, University of California, San Francisco 94143.

FEBS Letters
|November 12, 1990
PubMed

Insights

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes parkinsonian symptoms by converting to MPP+ in the brain. MPP+ damages mitochondria by inhibiting NADH dehydrogenase, leading to neurodegeneration.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Toxicology

Background:

  • 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin that induces parkinsonian symptoms in primates.
  • Understanding the biochemical mechanisms of MPTP neurotoxicity is crucial for Parkinson's disease research.

Purpose of the Study:

  • To review the biochemical events underlying MPTP neurotoxicity.
  • To elucidate the mechanism of MPTP-induced parkinsonism.

Main Methods:

  • Review of existing literature on MPTP metabolism and mechanism of action.
  • Analysis of biochemical pathways involving monoamine oxidase B (MAO-B) and NADH dehydrogenase.

Main Results:

  • MPTP is oxidized to MPP+ by MAO-B in glial cells.
  • MPP+ accumulates in dopamine neurons and inhibits mitochondrial NADH dehydrogenase.
  • Mitochondrial damage is the primary cause of MPTP-induced nigrostriatal cell death.

Conclusions:

  • MPTP neurotoxicity results from MPP+-induced mitochondrial dysfunction.
  • NADH dehydrogenase is the molecular target of MPP+.
  • Further research into the binding site of MPP+ may reveal therapeutic targets for Parkinson's disease.

Related Concept Videos

Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...